EGFR and neoplasm: In the present study we show that celecoxib enhances the antitumor efficacy of cetuximab in CRC and reduces colon cancer stem cells tumor subpopulation, supporting that the combination of EGFR and COX-2 inhibitors could improve current mCRC therapies.